Company / Operating Income
C4 Therapeutics, Inc. Operating Income History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$115.2M
FY2025
5-year range
-$139.0M / -$82.1M
FY2022-FY2025
Trend
+17.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$139M to -$115M over the past 2 years.
Based on SEC 10-K filings.
-$115M in FY2025.
Improved from -$139M to -$115M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 17.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$115.2M | +17.1% |
| FY2024 | -$139.0M | +0.0% |
| FY2023 | -$139.0M | -69.3% |
| FY2022 | -$82.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026